Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 13-14/2012

01.07.2012 | Kalzium in der kardialen Pathophysiologie

Calcium handling in human heart failure—abnormalities and target for therapy

verfasst von: Hannes Reuter, MD, Robert H. G. Schwinger, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2012

Einloggen, um Zugang zu erhalten

Summary

The fast cycling of calcium between internal stores and the myofilaments with rapid diffusion down steep concentration gradients provides the cellular basis for cardiac contraction and relaxation. In heart failure, the intracellular Ca2 + dynamics are impaired showing reduced systolic peak Ca2 +, elevated diastolic Ca2 + levels, and prolonged diastolic Ca2 + decay. The recognition that defects in the function of Ca2 + handling proteins are central to the pathogenesis of heart failure has attracted attention to these proteins as potential targets for therapy. Besides pharmacologic interventions including digitalis, ranolazine, levosimendan and others, cardiac gene therapy holds great promise and the recent clinical studies have proven the feasibility of this therapeutic approach. In this review, the rationale underlying modern therapies that modulate intracellular Ca2 + handling for the treatment of human heart failure are presented and discussed.
Literatur
1.
Zurück zum Zitat Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 1983;245:C1–14.PubMed Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 1983;245:C1–14.PubMed
2.
Zurück zum Zitat Matthes J, Jager A, Handrock R, et al. Ca2+-dependent modulation of single human cardiac L-type calcium channels by the calcineurin inhibitor cyclosporine. J Mol Cell Cardiol. 2004;36:241–55.PubMedCrossRef Matthes J, Jager A, Handrock R, et al. Ca2+-dependent modulation of single human cardiac L-type calcium channels by the calcineurin inhibitor cyclosporine. J Mol Cell Cardiol. 2004;36:241–55.PubMedCrossRef
3.
Zurück zum Zitat Satin J, Schroder EA, Crump SM. L-type calcium channel auto-regulation of transcription. Cell Calcium. 2011;49:306–13.PubMedCrossRef Satin J, Schroder EA, Crump SM. L-type calcium channel auto-regulation of transcription. Cell Calcium. 2011;49:306–13.PubMedCrossRef
4.
Zurück zum Zitat Yano M, Ono K, Ohkusa T, et al. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation. 2000;102:2131–6.PubMedCrossRef Yano M, Ono K, Ohkusa T, et al. Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation. 2000;102:2131–6.PubMedCrossRef
5.
Zurück zum Zitat Kho C, Lee A, Jeong D, et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 2011;477:601–5.PubMedCrossRef Kho C, Lee A, Jeong D, et al. SUMO1-dependent modulation of SERCA2a in heart failure. Nature. 2011;477:601–5.PubMedCrossRef
6.
Zurück zum Zitat Schwinger RH, Munch G, Bolck B, et al. Reduced Ca(2+)-sensitivity of SERCA2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol. 1999;31:479–91.PubMedCrossRef Schwinger RH, Munch G, Bolck B, et al. Reduced Ca(2+)-sensitivity of SERCA2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol. 1999;31:479–91.PubMedCrossRef
7.
Zurück zum Zitat Lou Q, Fedorov VV, Glukhov AV, et al. Transmural heterogeneity and remodeling of ventricular excitation-contraction coupling in human heart failure. Circulation. 2011;123:1881–90.PubMedCrossRef Lou Q, Fedorov VV, Glukhov AV, et al. Transmural heterogeneity and remodeling of ventricular excitation-contraction coupling in human heart failure. Circulation. 2011;123:1881–90.PubMedCrossRef
8.
Zurück zum Zitat Reuter H, Henderson SA, Han T, et al. The Na+-Ca2+ exchanger is essential for the action of cardiac glycosides. Circ Res. 2002;90:305–8.PubMedCrossRef Reuter H, Henderson SA, Han T, et al. The Na+-Ca2+ exchanger is essential for the action of cardiac glycosides. Circ Res. 2002;90:305–8.PubMedCrossRef
9.
Zurück zum Zitat Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–82.PubMedCrossRef Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–82.PubMedCrossRef
10.
Zurück zum Zitat Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105–10.PubMedCrossRef Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105–10.PubMedCrossRef
11.
Zurück zum Zitat Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure—the PERSIST study. Eur J Heart Fail. 2008;10:1246–54.PubMedCrossRef Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure—the PERSIST study. Eur J Heart Fail. 2008;10:1246–54.PubMedCrossRef
12.
Zurück zum Zitat Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51:2276–85.PubMedCrossRef Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51:2276–85.PubMedCrossRef
13.
Zurück zum Zitat Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304–13.PubMedCrossRef Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304–13.PubMedCrossRef
14.
Zurück zum Zitat Tang T, Gao MH, Roth DM, et al. Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy. Am J Physiol Heart Circ Physiol. 2004;287:H1906–12.PubMedCrossRef Tang T, Gao MH, Roth DM, et al. Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy. Am J Physiol Heart Circ Physiol. 2004;287:H1906–12.PubMedCrossRef
Metadaten
Titel
Calcium handling in human heart failure—abnormalities and target for therapy
verfasst von
Hannes Reuter, MD
Robert H. G. Schwinger, MD
Publikationsdatum
01.07.2012
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 13-14/2012
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-012-0117-9

Weitere Artikel der Ausgabe 13-14/2012

Wiener Medizinische Wochenschrift 13-14/2012 Zur Ausgabe

Kalzium in der kardialen Pathophysiologie

Calcium handling and ventricular tachyarrhythmias